Published in Health Econ on February 22, 1995
How should cost data in pragmatic randomised trials be analysed? BMJ (2000) 6.66
Laparoscopic versus open appendectomy: outcomes comparison based on a large administrative database. Ann Surg (2004) 2.95
The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Ann Rheum Dis (2004) 1.92
Cost-of-illness studies based on massive data: a prevalence-based, top-down regression approach. Eur J Health Econ (2015) 0.83
Outcome predictors in autism spectrum disorders preschoolers undergoing treatment as usual: insights from an observational study using artificial neural networks. Neuropsychiatr Dis Treat (2015) 0.80
Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. Support Care Cancer (2003) 0.80
Economic analysis of a multi-site prevention program: assessment of program costs and characterizing site-level variability. Prev Sci (2013) 0.76
Comparison of performance of four instruments in evaluating the effects of salmeterol on asthma quality of life. Eur Respir J (1995) 2.10
Access to coverage for high-risks in a competitive individual health insurance market: via premium rate restrictions or risk-adjusted premium subsidies? J Health Econ (2000) 1.07
Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1995) 1.06
"A built bed is a filled bed?" An empirical re-examination. Soc Sci Med (1989) 1.05
Multiyear diagnostic information from prior hospitalization as a risk-adjuster for capitation payments. Med Care (1996) 1.01
Deductibles in health insurance: can the actuarially fair premium reduction exceed the deductible? Health Policy (2000) 0.95
Towards a reinforced agency role of health insurers in Belgium and The Netherlands. Health Policy (1999) 0.91
Consumer information surplus and adverse selection in competitive health insurance markets: an empirical study. J Health Econ (1995) 0.90
Two-year bronchodilator treatment in patients with mild airflow obstruction. Contradictory effects on lung function and quality of life. Chest (1992) 0.89
Costs in the last year of life in The Netherlands. Inquiry (2001) 0.88
Methodological issues of patient utility measurement. Experience from two clinical trials. Med Care (1995) 0.87
Risk sharing as a supplement to imperfect capitation: a tradeoff between selection and efficiency. J Health Econ (2001) 0.87
Cost-effectiveness analysis of formoterol versus salmeterol in patients with asthma. Pharmacoeconomics (1998) 0.81
Cost effectiveness of inhaled corticosteroid plus bronchodilator therapy versus bronchodilator monotherapy in children with asthma. Pharmacoeconomics (1993) 0.81
Risk-adjusted capitation: recent experiences in The Netherlands. Health Aff (Millwood) (1994) 0.80
Mandatory high-risk pooling: an approach to reducing incentives for cream skimming. Inquiry (1996) 0.79
Risk-adjusted capitation payments for catastrophic risks based on multi-year prior costs. Health Policy (1997) 0.78
Mandatory pooling as a supplement to risk-adjusted capitation payments in a competitive health insurance market. Soc Sci Med (1998) 0.78
The introduction of deductibles for prescription drugs in a national health insurance: compulsory or voluntary? Health Policy (1995) 0.75
Risk sharing between competing health plans and sponsors. Health Aff (Millwood) (2001) 0.75
Ignoring small predictable profits and losses: a new approach for measuring incentives for cream skimming. Health Care Manag Sci (2000) 0.75